Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Orna Therapeutics is raising $221,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Barnes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orna Therapeutics
Orna Therapeutics was founded on groundbreaking research by Alex Wesselhoeft, Ph.D., and Daniel G. Anderson, Ph.D. from MIT and built by MPM Capital and BioImpact Capital, an investment management affiliate of MPM. Ornas proprietary circular RNA (oRNA) is engineered as linear RNA that self-circularizes. By taking a line and turning it into a circle, oRNA exhibits numerous advantages over traditional linear mRNA therapies such as simplified production, increased protein expression, and a superior immunogenicity profile. With proprietary lipid nanoparticles (LNPs), including those from Ornas joint venture with ReNAgade Therapeutics, an RNA delivery company, our technologies expand the possibilities of what RNA therapeutics can achieve.

To learn more about Orna Therapeutics, visit http://www.ornatx.com/

Contact:
Thomas Barnes, Chief Executive Officer
202-930-4762
tbarnes@ornatx.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved